


The Beginning
Dr Arti Barnes with IDPH

Management Across the Covid-19 spectrum



Boost immune responses

Monoclonal Antibodies

- Monoclonal antibodies against SARS-CoV-2 being studied for treatment and prevention
- Target spike protein of SARS-CoV-2
- Emergency Use Authorizations for treatment of ambulatory patients with mild to moderate COVID-19 at high risk of progression and within 10 days of symptom onset:
  - ✓Bamlanivimab
  - ✓Casirivimab + Imdevimab (2400 mg) – Regen-Cov
  - ✓Bebtelovimab (New)

FDA U.S. FOOD & DRUG ADMINISTRATION

Antiviral Effect of Monoclonal Antibodies

- In outpatients with mild to moderate COVID-19, bamlanivimab and casirivimab + imdevimab appear to accelerate decline in SARS CoV-2 level compared to placebo

Bamlanivimab vs placebo



Figure 1: SARS-CoV-2 viral load change from baseline by visit.

Difference statistically significant for intermediate dose

Casirivimab/imdevimab vs placebo



Largest reduction in viral load in participants seronegative at baseline

Who Should be Considered for Monoclonal Antibody Therapy?

Treatment - cont

Patient has mild to moderate COVID-19 with a positive SARS CoV-2 test result.

- Patient is within 10 days of symptom onset.
- Patient is not hospitalized or requiring oxygen therapy due to COVID-19 infection
- Patient is at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as a patient who meets at least one of the following criteria*:

  - Older age (≥65 years old), < 1 year old, obesity or being overweight, pregnancy, chronic kidney disease, DM, immunosuppressive disease, or immunosuppressive treatment, cardiovascular disease (including congenital heart disease), hypertension, chronic lung diseases (including COPD, asthma, interstitial lung disease, CF and pulmonary hypertension), sickle cell disease, neurodevelopmental disorders (cerebral palsy) or other conditions that confer medical complexity (genetic or metabolic syndromes and severe congenital anomalies), having a medical-related technological dependence (tracheostomy, gastrostomy, or non-COVID positive pressure ventilation)

    *Other medical conditions or factors (race/ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization under the EUA IS NOT limited to the medical conditions or factors listed above. For additional info on medical conditions and factor associated with increased risk of progression to severe COVID see https://www.cdc.gov/coronavirus/2019-ncov/need-extraprecautions/people-with-medical-conditions.html. Healthcare providers should consider the benefit/risk for an individual patient.

Treatment - cont

Post-Exposure Prophylaxis: (only check if the patient meets all these criteria):**

Patient is at high risk of progression to severe COVID-19 including hospitalization or death, AND is:

Not fully vaccinated or not expected to mount an adequate immune response to complete SARSCoV-2 vaccination (individuals with immunocompromising conditions including those taking immunosuppressive medications) **and**

Has been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per CDC **or**

Who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (nursing homes, prisons)

**PEP is not a substitute for vaccination nor is it authorized for pre-exposure prophylaxis for prevention. By signing below I have certified that the patient meets all criteria and is a candidate for monoclonal antibody therapy for COVID-19. I give my authorization for the following protocol to be followed:


ANTIBODY TREATMENT TO PREVENT SEVERE COVID-19
ARE YOU ELIGIBLE?
HAVE YOU TESTED POSITIVE FOR COVID-19?
NO
YES
ARE YOU HOSPITALIZED OR ON OXYGEN?
NO
YES
DO YOU HAVE COVID-19 SYMPTOMS?
NO
YES
DID YOUR SYMPTOMS START IN THE PAST 10 DAYS?
NO
YES
ARE YOU 12 YEARS OF AGE OR OLDER AND WEIGH 88 POUNDS OR MORE?
NO
YES
ARE YOU AT RISK FOR SEVERE DISEASE?*
NO
YES
YOU ARE NOT ELIGIBLE
YOU MAY BE ELIGIBLE
mAb Colorado
medschool.cuanschutz.edu/mab-colorado
*ANY RISK CONDITIONS
Older age —65 years of age or older
Obesity or being overweight — adults with body mass index of 25 or more, children in the 85th percentile for their age and gender based on CDC growth charts
Pregnancy
Chronic kidney disease
Diabetes
Immunosuppressive disease/ receiving immunosuppressive treatment
Cardiovascular disease or hypertension
Chronic respiratory disease
Neurodevelopmental disorders
Any other medical condition or factor — including race or ethnicity — associated with increased risk
For more information or to find an infusion center near you:
Call 1-877-332-6585 (English) or 1-877-366-0310 (Spanish), or visit combatcovid.hhs.gov.
6/16/2021

Why utilize Home Care

- Decrease transmission risk
- Increase the availability to patients
- Decrease overload in OP infusions
- Decrease hospitalization due to COVID
- Ease for the patient

Address Cost (& Access), Staff, Documentation

- ✓ There is no cost for the medication
  - federal government pays for the medication
  - administration fee is covered by Medicare, Medicaid and commercial insurance
- ✓ Staff Resources
- ✓ Documentation and Billing



- Principal Program
- Revenue/Charge Set Up
- Order Set
- Protocol
- Staff Education

Dictionary: Patient Programs

Patient Program Main

Patient Programs

Identifier	mAB Covid
Active	Yes
Name	Monoclonal Antibody COVID

Service Lines	Default Admitting Resource Class
Home Health	Nursing

General Ledger

Component Value	
Component Description	

Interface Mapping

Interface Process	Value

Dictionary: Revenue Code



Dictionary: Visit Type



Dictionary: Charge

Charge Details | Service Line Office | GL Override Account

Charge Details

* Name	39000020
* Description	mAb SN visit
* Active	Yes
* Charge Class	Visit Type
* Editable Charge	Yes
* Billable	Yes
* Revenue Code	771

Default Codes

Code Type	Code	Code Modifier	* Effective Date
HCPCS	M0244		09/14/21

Default Rates

* Effective Date	Cost	* Unit Type	* Unit Factor	* List Price
09/14/21	150.00	Each	1	1,125.00

Legacy Keys

Type	Value

Dictionary: Standing Order/Order Set



Dictionary: Protocol



Staff Education:

- Intake
- Review of Infection Control
- Review of Telehealth Kits
- Storage and Transportation of maB
- Administration
- Documentation

Obstacles/Work Flow

POC
Overlapping Visits

Cheryl Adams, BSN, MBA
At-Home Health Care
cheryl@spartahospital.com
Tele: 618-443-2390